Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of neurosteroids and androgens throughout different life stages, noting the potential disruptions caused by 5α-reductase inhibitors like finasteride, but no new clinical results are reported.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

Large prostate patients more likely to have hair loss.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This review discusses the nutrient profile and potential health benefits of pumpkin and watermelon seeds, concluding they are underutilized and could be developed into various nutraceuticals.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This article reviews the role of 5α-reductase in cutaneous hyperandrogenism and the potential of 5α-reductase inhibitors and antiandrogens in treating conditions like hirsutism and male-pattern baldness, reporting no clinical results.

In this uncontrolled study, ivermectin treatment for scabies resulted in the resolution of symptoms and negative skin scrapings in most patients at follow-ups.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.